MediPrint Ophthalmics
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
9899 Hibert St Ste A, San Diego, Califor...Phone Number
(858) 385-0800Website
www.mediprintlens.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About MediPrint Ophthalmics
MediPrint Ophthalmics is a San Diego, California-based clinical stage eye care pharmaceutical company focused on enhancing vision for life.Explore more
MediPrint Ophthalmics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MediPrint Ophthalmics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at MediPrint Ophthalmics
Funding: Get notified immidiatlly once MediPrint Ophthalmics has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on MediPrint Ophthalmics recently announced quarterly report
Product Launch: Get notified when MediPrint Ophthalmics launches new products
Click to see if MediPrint Ophthalmics had a recent Job posting/layoffs
Check if MediPrint Ophthalmics has recently received funding, and reach out quickly before it becomes old news!
Check out if MediPrint Ophthalmics is spiking on competitors!
MediPrint Ophthalmics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at MediPrint Ophthalmics
Find more new buyers
Compare Similar Companies to MediPrint Ophthalmics
Compare insights from companies similar to MediPrint Ophthalmics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
MediPrint Ophthalmics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MediPrint Ophthalmics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MediPrint Ophthalmics.
MediPrint Ophthalmics financials insights
Gather financial insights about MediPrint Ophthalmics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Angel/Seed
$4.5M
2022
Series A
$2.5M
MediPrint Ophthalmics Tech Stack
A closer look at the technologies used by MediPrint Ophthalmics
MediPrint Ophthalmics News & Media
MediPrint Ophthalmics Advances Glaucoma Program, Expands Patent Portfolio, and Prepares for Key Industry Presentation
SAN DIEGO--(BUSINESS WIRE)--MediPrint® Ophthalmics, a clinical-stage ophthalmic drug delivery company, continues to advance its innovative glaucoma program following the successful completion of its Phase 2b clinical trial for LL-BMT1. As the company progresses towards the next phase of development, MediPrint anticipates meeting with the U.S. Food and Drug Administration (FDA) in 2025 to discuss preparations for Phase 3 clinical studies. Regulatory Progress and Path Toward Phase 3 Following theMediPrint Ophthalmics Presents Promising Results from Phase 2b Clinical Trial of LL-BMT1 for Glaucoma at American Academy of Optometry
INDIANAPOLIS--(BUSINESS WIRE)-- #clinicaltrial--MediPrint® Ophthalmics (MediPrint), a clinical-stage ophthalmic drug delivery company based in San Diego, announced the results of the Company’s Phase 2b clinical trial of LL-BMT1. Employing a novel 3D printed, drug-eluting contact lens for sustained delivery of bimatoprost and hyaluronic acid, the clinical trial achieved all Phase 2b endpoints. In a presentation by Dr. Ian Ben Gaddie at the American Academy of Optometry’s annual meeting in IndianaMediPrint® Ophthalmics Announces Successful Completion of Its Phase 2b Glaucoma Clinical Study with Positive Results.
SAN DIEGO--(BUSINESS WIRE)--MediPrint® Ophthalmics, a clinical-stage ocular drug delivery platform technology focused on transforming ocular drug delivery, announces the completion of its Glaucoma SIGHT-2, Phase 2b study. The Phase IIb trial was an active-controlled, randomized, dose-finding, multi-center study, evaluating the Company’s lead candidate (LL-BMT1) versus a control group on bimatoprost 0.01% ophthalmic solution. LL-BMT1 is a novel, preservative-free, weekly drug-eluting contact lenFormer CooperVision Leader Tom Bender Joins MediPrint Ophthalmics as Strategic Advisor
SAN DIEGO--(BUSINESS WIRE)-- #DrugElutingLenses--Tom Bender, former CooperVision exec, joins MediPrint Ophthalmics as an advisor for innovative drug-delivering contact lenses.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MediPrint Ophthalmics
Sign Up For FreeTo access detailed company insights
MediPrint Ophthalmics is a San Diego, California-based clinical stage eye care pharmaceutical company focused on enhancing vision for life.... Read More
